Which dosing form is used for denosumab in osteoporosis?

• A. Intravenous infusion weekly.
• B. Oral tablet daily.
• C. Subcutaneous injection every 6 months.
• D. Topical cream monthly.

Answer: (C)

Denosumab is a monoclonal antibody that inhibits RANKL, which slows osteoclast formation and bone resorption to reduce fracture risk. Because of its protein nature, it isn’t effectively absorbed if taken orally, so it must be given by injection to reach the bloodstream and bone tissue. The approved approach for osteoporosis is a subcutaneous injection every six months, providing a long-lasting effect with convenient dosing. An oral tablet daily would not achieve reliable bioavailability, a topical cream would not reach bone, and an intravenous infusion weekly isn’t how this drug is dosed for osteoporosis.